Our group has pioneered the use of small hair samples to monitor adherence to antiretroviral (ARV) therapy in HIV infection. We have demonstrated that hair concentrations of ARVs, which monitor long-term exposure, are stronger predictors of treatment success than self-reported adherence or plasma ARV levels in large cohorts of HIV-infected patients. Moreover, we have shown high sensitivity and specificity for tenofovir (TFV) detection in hair in a PrEP trial and have demonstrated a strong correlation between TFV dosing and TFV concentrations in hair. Recent data from HIV pre-exposure prophylaxis (PrEP) trials and prevention of mother to child transmission (PMTCT) settings indicate that adherence to prophylactic ARVs when assessed by more objective biomarkers of adherence (e.g. drug levels in plasma, peripheral blood mononuclear cells (PBMCs), breast milk, cord blood) is not always concordant with self report or other more traditional adherence measures, such as pill counts. Hair specimens are easy to collect, store and analyze, providing substantial feasibility, safety and accuracy advantages over other objective methods to monitor adherence, especially in resource-limited settings. This proposal seeks to extend our approach of using hair ARV levels to monitor adherence from the HIV treatment to the prevention setting, partnering with two large, ongoing NIH-funded global HIV prevention trials to further test our methodology in a cost-effective manner.
Aim 1 adds hair measures for TFV and emtricitabine (FTC) adherence monitoring into the active oral arms of VOICE (Vaginal and Oral Interventions to Control the Epidemic), an ongoing MTN-sponsored PrEP trial in African women to assess the effectiveness and safety of oral TFV-based products or vaginal TFV gel in preventing HIV acquisition.
Aim 2 adds hair measures for nevirapine (NVP) monitoring into the daily infant NVP prophylaxis arm of PROMISE BF (Promoting Maternal and Infant Survival Everywhere), a recently- launched IMPAACT-sponsored PMTCT trial in breastfeeding (BF) infants. We will analyze the relevant prophylactic ARV level(s) in hair in each trial once outcomes are available and analyze these hair levels as predictors for HIV seroconversion (aims 1A, 2A) and ARV toxicity (aims 1B, 2B) in multivariate models, comparing hair levels to self-report, pill counts and plasma ARV levels. We will also monitor hair TFV levels in women receiving vaginal TFV gel product to assess for systemic absorption (aim 1C) in VOICE and assess correlations between hair and breast milk ARV levels in the pharmacology sub-study of PROMISE BF (aim 2C). Finally, for Aim 3, we will develop a low-cost point-of care testing method to analyze ARV levels in hair and compare this assay to our validated and sensitive method using liquid chromatography/tandem mass spectrometry. At study completion, we expect to have validated hair levels of ARVs as a novel and practical biomarker of adherence which can easily be implemented into public health programs geared towards HIV prevention and prevention of maternal to child transmission.
HIV medications (antiretrovirals) taken by HIV-negative people can reduce the risk of getting HIV through sex in adults and through breastfeeding in infants. However, HIV-uninfected individuals may not be motivated to take medications every day. Recent clinical trials in HIV prevention have shown that HIV-negative people don't always tell investigators when they don't take the medications as prescribed, so ongoing prevention trials need more objective ways to measure adherence, such as measuring drug levels. We have proven that measuring antiretroviral levels in small cut pieces of scalp hair are excellent measures of drug adherence. Hair samples are easy to collect, store and analyze. Cutting small hair samples is painless and avoids drawing blood, a particular advantage in babies. This project will plug our hair measures into two ongoing large HIV prevention trials in Africa and India (one in women and one in infants) to more accurately measure adherence in these trials and in real-world HIV prevention programs. Our innovative way of monitoring medication levels in hair has public health relevance not only for HIV, but for many chronic disease states.
|Saberi, Parya; Neilands, Torsten B; Ming, Kristin et al. (2017) Strong Correlation Between Concentrations of Antiretrovirals in Home-Collected and Study-Collected Hair Samples: Implications for Adherence Monitoring. J Acquir Immune Defic Syndr 76:e101-e103|
|Gandhi, Monica; Murnane, Pamela M; Bacchetti, Peter et al. (2017) Hair levels of preexposure prophylaxis drugs measure adherence and are associated with renal decline among men/transwomen. AIDS 31:2245-2251|
|Chawana, Tariro D; Gandhi, Monica; Nathoo, Kusum et al. (2017) Defining a Cutoff for Atazanavir in Hair Samples Associated With Virological Failure Among Adolescents Failing Second-Line Antiretroviral Treatment. J Acquir Immune Defic Syndr 76:55-59|
|Seifert, Sharon M; Castillo-Mancilla, Jose R; Erlandson, Kristine et al. (2017) Adherence biomarker measurements in older and younger HIV-infected adults receiving tenofovir-based therapy. J Acquir Immune Defic Syndr :|
|Pintye, Jillian; Bacchetti, Peter; Teeraananchai, Sirinya et al. (2017) Brief Report: Lopinavir Hair Concentrations Are the Strongest Predictor of Viremia in HIV-Infected Asian Children and Adolescents on Second-Line Antiretroviral Therapy. J Acquir Immune Defic Syndr 76:367-371|
|Markowitz, Martin; Grossman, Howard; Anderson, Peter L et al. (2017) Newly Acquired Infection With Multidrug-Resistant HIV-1 in a Patient Adherent to Preexposure Prophylaxis. J Acquir Immune Defic Syndr 76:e104-e106|
|Koss, Catherine A; Bacchetti, Peter; Hillier, Sharon L et al. (2017) Differences in Cumulative Exposure and Adherence to Tenofovir in the VOICE, iPrEx OLE, and PrEP Demo Studies as Determined via Hair Concentrations. AIDS Res Hum Retroviruses :|
|Abaasa, Andrew; Hendrix, Craig; Gandhi, Monica et al. (2017) Utility of Different Adherence Measures for PrEP: Patterns and Incremental Value. AIDS Behav :|
|Gerona, Roy; Wen, Anita; Koss, Catherine et al. (2016) A multi-analyte panel for non-invasive pharmacokinetic monitoring of second-line anti-tuberculosis drugs. Int J Tuberc Lung Dis 20:991-2|
|Gerona, Roy; Wen, Anita; Chin, Aaron T et al. (2016) Quantifying Isoniazid Levels in Small Hair Samples: A Novel Method for Assessing Adherence during the Treatment of Latent and Active Tuberculosis. PLoS One 11:e0155887|
Showing the most recent 10 out of 33 publications